Depomed paying $1.05bn for Janssen's US Nucynta rights
This article was originally published in Scrip
Newark, California-based Depomed will pay Johnson & Johnson's Janssen Pharmaceuticals subsidiary $1.05bn to buy the US rights for all approved formulations of the pain drug Nucynta (tapentadol), which Janssen licensed in 2003 and co-developed with Grunenthal.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.